De novo mutations within metabolism networks of amino acid/protein/energy in Chinese autistic children with intellectual disability

Wen-Xiong Chen1†, Bin Liu2,3†, Lijie Zhou4, Xiaoli Xiong2, Jie Fu2, Zhi-Fang Huang1, Ting Tan2, Mingxi Tang5, Jun Wang4 and Ya-Ping Tang2,4,6*

Abstract

Background: Autism spectrum disorder (ASD) is often accompanied by intellectual disability (ID). Despite extensive studies, however, the genetic basis for this comorbidity is still not clear. In this study, we tried to develop an analyzing pipeline for de novo mutations and possible pathways related to ID phenotype in ASD. Whole-exome sequencing (WES) was performed to screen de novo mutations and candidate genes in 79 ASD children together with their parents (trios). The de novo altering genes and relative pathways which were associated with ID phenotype were analyzed. The connection nodes (genes) of above pathways were selected, and the diagnostic value of these selected genes for ID phenotype in the study population was also evaluated.

Results: We identified 89 de novo mutant genes, of which 34 genes were previously reported to be associated with ASD, including double hits in the EGF repeats of NOTCH1 gene (p.V999M and p.S1027L). Interestingly, of these 34 genes, 22 may directly affect intelligence quotient (IQ). Further analyses revealed that these IQ-related genes were enriched in protein synthesis, energy metabolism, and amino acid metabolism, and at least 9 genes (CACNA1A, ALG9, PALM2, MGAT4A, PCK2, PLEKHA1, PSME3, ADI1, and TLE3) were involved in all these three pathways. Seven patients who harbored these gene mutations showed a high prevalence of a low IQ score (< 70), a non-verbal language, and an early diagnostic age (< 4 years). Furthermore, our panel of these 9 genes reached a 10.2% diagnostic rate (5/49) in early diagnostic patients with a low IQ score and also reached a 10% diagnostic yield in those with both a low IQ score and non-verbal language (4/40).

Conclusion: We found some new genetic disposition for ASD accompanied with intellectual disability in this study. Our results may be helpful for etiologic research and early diagnoses of intellectual disability in ASD. Larger population studies and further mechanism studies are warranted.

Keywords: Autism spectrum disorder, Whole-exome sequencing, De novo mutations, Pathways, Intellectual disability, Intelligence quotient

*Correspondence: yptang12@gzhmu.edu.cn

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
behaviors. Other than these core symptoms, ASD may be accompanied by many other problems, such as intellectual disability (ID) [1], deficits in fine motor skills, speech language delay [2], metabolic disturbance of amino acids [3] or fatty acid [4], and epilepsy [5]. In addition, gastrointestinal problems, epilepsy, and sleep disorders are common phenotypes in ASD [6].

Twin and family studies revealed that genetic factors compose a major contributor for ASD. Those genetic effects can be acquired via a “new” mutation occurring in probands (de novo mutation) or harmful variants transmitted from parents. By using large-scale genome sequencing, various de novo variants have been identified in a number of genes that may be associated with the pathogenesis of ASD. For example, de novo mutations affecting GABAergic neuronal circuits [7], cytoskeletal organization, ion transport [8], ubiquitination pathway, protein synthesis and degradation, the development, formation, and function of synapses [6], and the balance in excitation and inhibition synaptic input [9], have been reported to be associated with the occurrence of ASD, demonstrating the role of de novo variants in the etiology of ASD. More interestingly, some de novo altering genes were also indicative of other clinical entities [9]. For instance, genes located on the X chromosome have been reported to contribute to ASD subgroups with ID [10], while other ASD genes are thought to be related to speech-impairment [11]. Some researchers also found an etiological overlap between ASD and epilepsy [12]. Additionally, an ASD-associated de novo mutation found in dopamine transporter (DAT T356M) can alter striatal dopamine neurotransmission and cause dopamine-dependent behaviors in mice, which is also seen in attention-deficit/hyperactivity disorder (ADHD) [13]. Therefore, tests of de novo mutation are thought to be contributable significantly to ASD research and diagnosis [14–16]. However, the genetic basis of these comorbidities in ASD remains largely unknown. Linking genetic factors to a certain symptom or particular sets of ASD may be more useful for etiologic research and potentially for diagnosis purpose. Among these comorbidities, ID is particularly relevant due of its high prevalence, high degree of heritability [10], and long-term effects on quality of life, even after entering adulthood [1].

We therefore implemented whole-exome sequencing (WES) of ASD samples in an attempt to establish a genetic architecture of ASD patients who are accompanied by certain clinical entities such as ID. To this end, we developed an analyzing pipeline to search for de novo mutation and pathways that could be related to ID phenotype in ASD.

Results

Clinical characteristics of subjects

In total, 79 ASD families including siblings without ASD and both healthy parents were collected in this study. Among these, 77 families were trios, while other two were quarters. As for probands, there were 72 boys and 7 girls, with mean age of 3.18 ± 1.24 years. Clinical information of patients was collected during diagnostic and follow-up visits. A considerable proportion of patients were found to have low developmental quotient (DQ) or intelligence quotient (IQ) (< 60, ~ 46.5%), non-verbal language (~ 61.0%), walking age equal with or later than 12 months (~ 84.9%), metabolic disturbance in plasma of short-median-chain acylcarnitines (~ 73.3%), thyroid hormones (~ 24.7%), and long-chain acylcarnitines (~ 17.3%); and as for plasma amino acid, the prevalence of aberrant hydroxyproline was common (~ 41.3%). The abovementioned phenotypes were further analyzed. We found that patients who were diagnosed at < 3 years of age (Fisher’s exact test,  \( P = 6.15 \times 10^{-7} \), odds ratio [OR] = 13.96), or DQ/IQ < 60 (Fisher’s exact test,  \( P = 0.038 \), OR = 2.77) tended to have worse language ability, but no significant association was observed between diagnosed age and walking age (Fisher’s exact test,  \( P = 0.12 \), OR = 2.81).

Identification of de novo mutations

All subjects in this study were tested by whole-exome sequencing. On average, we produced 16.2 GB of raw reads for each sample, and 96.6% of them were mapped to the human reference genome (hg19 version) by Burrows–Wheeler Aligner (BWA). The coverage of the targeted sequences per sample ranged from 98 × to 171 × (average 119 ×), and the coverage of targeted sequences that covered at least 10 times of each sample ranged from 92.9 to 95.8% (average 94.8%, Additional file 1: Table S1). All the data showed that the sequencing data quality was relatively good for de novo mutation detection. Moreover, no exceedance of Mendelian errors was found in our data (Additional file 1: Figure S1), and all these 79 ASD families had identification of de novo mutations performed.

After validated by Sanger sequencing, we confirmed 82 de novo coding single nucleotide variants (SNVs) and 7 de novo coding insertions and deletions (INDELS) (Additional file 2: Table S2). Among these mutations, one missense and one stop-loss mutation occurred in unaffected siblings (the last two mutations in Additional file 2: Table S2). Considering the limited mutation number in siblings, totally 87 de novo events, including 57 missense mutations, 19 silent SNVs, and 4 stop gains, and 7 INDELS in probands were further analyzed. None of these abovementioned mutations...
were found in our in-house exome sequencing database including 2000 Han Chinese.

Additionally, we performed splicing site prediction to detect potential splice sites (detailed in Methods), 3 silent and 4 missense mutations passed our threshold, and were marked as silent-splicing and missense-splicing, separately. Meanwhile, we analyzed inherited SNVs and INDELs possibly related to ASD and found 39 homozygous mutations, 3025 compound heterozygous mutations, and X-linked mutations (data not shown). We have analyzed these inherited mutations; however, no common characteristics in pathways between the inherited and de novo mutations were found in this study. Therefore, these inherited mutations will be analyzed in reports to follow.

There were about 65% of children (51/79) carrying at least one de novo SNV or INDEL. The number of each family (1.01 for each individual, on average) followed a Poisson distribution (Additional file 1: Figure S2), which suggested that there was no obvious system bias in the process of sequencing and de novo mutation detection. The average number and rate of de novo SNV/INDEL were 1.01 /0.089 and 1.51 × 10⁻⁸/1.32 × 10⁻⁹, respectively (Additional file 1: Table S3).

Compared with general mutations, the de novo mutations found in ASD children are more inclined to have a prominently higher ratio between non-synonymous (including missense, stop gain, canonical and predicted splicing sites) and synonymous de novo SNVs (NS:S = 4.0), which exceeds the expected value under a random model (NS:S = 2.85 × 10⁻³) [9], and private inherited mutations (NS:S = 1.87, P = 2.89 × 10⁻³) (Additional file 1: Table S4). Simultaneously, the rate of LoF mutations (loss of function mutations, including stop gain, canonical and predicted splicing sites, and frameshift INDEL, which result in the gene product having less or no function) of de novo mutations found in our data are observed to be much higher than that of private inherited mutations (P = 1.60 × 10⁻⁷), and that of de novo mutations found in the reported control [9] (P = 2.89 × 10⁻³) (Additional file 1: Table S4).

Consistent with previous ASD studies [17], we found NOTCH1 gene recurrently mutated in 2 families, p.V999M and p.S1027L located in EGF repeats (EGF_CA domain, cd00054, Fig. 1). This gene plays an important role in NOTCH signaling pathway and is essential for neural development [18]. Besides, five other genes known to be associated with the occurrence of ASD (CACNA1A [19], CHRM3 [20], CNOT3 [21], EPHA6 [22], and CDH2

![Fig. 1 Schematic diagram and potential roles of de novo mutations in NOTCH1 genes in neurodevelopmental diseases. A. Schematic diagram of NOTCH1 gene, and de novo mutations (p.V999M and p.S1027L) found in this study. B. The potential roles of NOTCH1 signaling in neurodevelopmental diseases. This figure was adapted from Sanchez-Martin and Ferrando [24] and Arumugam et al. [25]](image-url)
Table 1 Genes with de novo harmful mutations in this study and reported database

| Gene      | This study | ASD virulence gene | ASD-related gene | Mental disease-related gene | Developmental disease-related gene | Combined* | References |
|-----------|------------|--------------------|------------------|----------------------------|-----------------------------------|----------|------------|
|           |            | Lof/Mis CNV N/Y    | Lof/Mis CNV N/Y  | Lof/Mis CNV N/Y            | Lof/Mis CNV N/Y                   |          |            |
| NOTCH1    | 0 2 0 0 0 Y| 0 0 0 0 N          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 2        | [17]       |
| Recurrent in this study |
| CACNA1A   | 1 0 1 0 0 Y| 0 0 0 0 N          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         |          |            |
| CHRM3     | 0 1 0 0 0 Y| 0 0 0 0 N          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [20];[28]  |
| CNOT3     | 0 1 0 0 0 Y| 0 0 0 0 N          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [21];[29];[30] |
| EPHA6     | 0 1 0 0 0 Y| 0 0 0 0 N          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [22]       |
| CDH2      | 0 1 0 0 0 Y| 0 0 0 0 N          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [23];[31]  |
| KIF5C     | 0 1 0 0 0 N| 0 1 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 3        | [32]       |
| KIF1A     | 0 1 0 0 0 N| 0 1 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 2        | [33]       |
| IKZF4     | 0 1 0 0 0 N| 0 0 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 2        | [34]       |
| SEC31B    | 0 1 0 0 0 N| 0 0 1 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 2        | [35]       |
| LMO7      | 1 0 0 0 0 Y| 0 0 0 0 N          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [36]       |
| VNCBP2    | 0 1 0 0 0 N| 0 0 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [37]       |
| PALM2     | 1 0 0 0 0 N| 0 0 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [38]       |
| ALG9      | 0 1 0 0 0 N| 0 0 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [39]       |
| WDTC1     | 0 1 0 0 0 N| 0 0 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [40]       |
| UBR4      | 0 1 0 0 0 N| 0 0 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [41];[42] |
| MNL1      | 0 1 0 0 0 N| 0 0 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [43]       |
| CRESB5    | 0 1 0 0 0 N| 0 0 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [44]       |
| ACK1      | 0 1 0 0 0 N| 0 0 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [45]       |
| TLE3      | 1 0 0 0 0 N| 0 0 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [46]       |
| ARID5B    | 1 0 0 0 0 N| 0 0 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [47]       |
| PHACTR3   | 0 1 0 0 0 N| 0 0 0 0 Y          | 0 0 0 0 N        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | dbGaP: phs000267.v5.p2 (NIMH Autism Genome Project) |
| HOMER2    | 0 1 0 0 0 N| 0 0 0 0 N          | 0 0 0 0 Y        | 0 0 0 0 Y                  | 0 0 0 0 Y                         | 1        | [48]; OMIM:616707 |
| XPNPEP1   | 1 0 0 0 0 N| 0 0 0 0 N          | 0 0 0 0 Y        | 0 0 0 0 Y                  | 0 0 0 0 Y                         | 1        | [49]       |
| PTPRM     | 0 1 0 0 0 N| 0 0 0 0 N          | 0 0 1 0 Y        | 0 0 0 0 N                  | 0 0 0 0 N                         | 2        | [50]       |
| MFAP1     | 0 1 0 0 0 N| 0 0 0 0 N          | 0 0 1 0 Y        | 0 0 0 0 N                  | 0 0 0 0 N                         | 2        | [51]       |
| SEC31A    | 0 1 0 0 0 N| 0 0 0 0 N          | 0 1 0 0 Y        | 0 0 0 0 N                  | 0 0 0 0 N                         | 2        | [52]       |
| MASPI1    | 0 1 0 0 0 N| 0 0 0 0 N          | 0 0 0 0 Y        | 0 0 0 0 Y                  | 0 0 0 0 Y                         | 1        | [53]       |
| CFH       | 0 1 0 0 0 N| 0 0 0 0 N          | 0 0 0 0 Y        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [54]       |
| YWHAQ     | 0 1 0 0 0 N| 0 0 0 0 N          | 0 0 0 0 Y        | 0 0 0 0 N                  | 0 0 0 0 N                         | 1        | [55]       |
Table 1 (continued)

| Gene   | This study | ASD virulence gene | ASD-related gene | Mental disease-related gene | Developmental disease-related gene | Combined* | References |
|--------|------------|--------------------|------------------|-----------------------------|-----------------------------------|-----------|------------|
|        | Lof Mis   | Lof Mis CNV N/Y    | Lof Mis CNV N/Y  | Lof Mis CNV N/Y             | Lof Mis CNV N/Y                   | Lof Mis/CNV (ALL diseases) |           |
| MGAT4A | 1 0 0 0 0 N| 0 0 0 N           | 0 0 0 Y          | 0 0 0 N                     | 0 0 0                                 | 1          | [56]       |
| TMEM8B | 0 1 0 0 0 N| 0 0 0 N           | 0 0 0 Y          | 0 0 0 N                     | 0 0 0                                 | 1          | [57]       |
| ABCAS5 | 0 1 0 0 0 N| 0 0 0 N           | 0 0 0 Y          | 0 0 0 N                     | 0 0 0                                 | 1          | [58]       |
| LYST   | 0 1 0 0 0 N| 0 0 0 N           | 0 0 0 Y          | 0 0 0 N                     | 0 0 0                                 | 1          | [59]; OMIM214500 |
| POU2F2 | 0 1 0 0 0 N| 0 0 0 N           | 0 0 0 Y          | 0 0 0 N                     | 0 0 0                                 | 1          | [60]       |
| NOL6   | 0 1 0 0 0 N| 0 0 0 N           | 0 0 0 Y          | 0 0 0 N                     | 0 0 0                                 | 1          | MCID#: ATS383 MIFTS: 37 |

All mutations in this table mean de novo mutations found in cases

*Combined number of mutations including this study and the references cited

1 MalaCards database: https://www.malacards.org/
2 The database of Genotypes and Phenotypes (dbGaP): https://www.ncbi.nlm.nih.gov/gap/
3 OMIM: Online Mendelian Inheritance in Man: https://www.ncbi.nlm.nih.gov/omim
were detected. We also found 16 genes associated with ASD, as shown in Table 1. Because the etiology of ASD and ID overlaps genetically [10], these abovementioned 22 genes might directly affect patients’ DQ/IQ.

Additionally, there were other eight de novo altering genes reported in mental diseases (KCNJ13, H2AFX, ZYYX, MAST2, MARK2, ADI1, PLEKHA1, and PCK2) [61–64], and four ones associated with developmental diseases (PDE3B, PIEZO1, HEYL, and CELSR1) [65–67].

We then further compared de novo mutations in diverse sub-population based on the clinical information, such as diagnosed early (<3 years), walking later (>12 months), DQ/IQ (<60), language impairment, and abnormal plasma levels of short-chain/long-chain acylcarnitine, hydroxyproline, and thyroid function shown as Additional file 1: Table S5. Compared with other patients, LoF mutations were more likely to occur in those with abnormal plasma thyroid function levels (Fisher’s test, \( P = 4.27 \times 10^{-3} \), OR = 11.10).

De novo disruptions of genes and pathways in subgroups in ASDs

Eighty-six de novo altering genes were annotated by GO (http://www.geneontology.org) and KEGG pathway database (http://www.genome.jp/kegg/pathway.html) and were grouped into five combined pathways, which were related to protein synthesis, pressure, energy metabolism, and amino acid metabolism, respectively (Additional file 2: Table S6).

We performed association analyses between the above pathways and the ID phenotype (DQ/IQ <60). And we found that the pathways related to protein synthesis, energy metabolism, and amino acid metabolism were significantly associated with the DQ/IQ levels (\( P \) values 0.019, 0.008, and 0.034, respectively) (Table 2).

Protein–protein interaction networks and mutations on key networks

For all genes with potential harmful de novo mutations, protein–protein interaction networks were predicted by DAPPLE (Disease Association Protein–Protein Link Evaluator) and STRING (http://string-db.org). There were more than 40 nodes in the protein–protein interaction networks (Fig. 2). Most of these nodes (genes) are relative to ASD, mental, or developmental diseases.

Interestingly, nine genes in these networks (CACNA1A, ALG9, PALM2, MGAT4A, PCK2, PLEKHA1, PSME3, ADI1, and TLE3) are concurrently involved in all above important pathways (protein synthesis, energy metabolism, and amino acid metabolism). All of these 9 genes were reported to be related to brain development. For example, 4 of them are relevant to ASD (CACNA1A, ALG9, PALM2, and TLE3). And the other 4 genes have been associated with schizophrenia (MGAT4A [56]), Leigh syndrome (ADI1, OMIM: 256,000), congenital hypomyelinating neuropathy (PLEKHA1, OMIM: 605,253), and ID (PCK2 [64]), respectively. Additionally, another gene PSME3 is also involved in the brain development, which is an e-QTR loci for the expression on hippocampus, basal ganglia, frontal cortex, cerebellum, and anterior cingulate cortex, and so on [56].

Moreover, cases that carried these mutations were all males and showed a high prevalence of DQ/IQ<70 (6/7), non-verbal language (5/7), and an early diagnostic age (<4 years, 7/7) (Table 3). Combined with the above results, it implies that the metabolism pathways of amino acid/protein/energy are relative with the etiology of intellectual disability in ASD.

Furthermore, our panel of these 9 altering genes reached a 10.2% diagnostic rate (5/49) in early diagnostic patients with a low DQ/IQ value and also reached a 10% diagnostic yield (4/40) in patients with both a low DQ/IQ score and a non-verbal language. Our results suggested a diagnostic value of De novo mutations within metabolism networks of amino acid/protein/energy in ASD/ID comorbidity.

The expression patterns of major disrupted pathway genes in different brain tissues

We investigated the expression level of all de novo genes based on BrainSpan (http://www.brainspan.org/static/download.html) and BrainStars (http://brainstars.org/). The expressed genes in specific brain regions (including CB, CBC, HIP, STR, AMY, and PIT) were defined by RPKM>5 (BrainSpan: CB, CBC, HIP, STR, AMY) or top 25% expression (BrainStars: PIT). We found that the genes involved in protein synthesis, such as YWHAQ, H2AFX, CDH2, and KIF1A/KIF5C, were highly expressed in different brain regions at all periods (Additional file 1: Figure S3). As for the genes were involved in energy metabolism, such as PSMES, SEC31A, and WDTC1, their expressions were not significantly varied in different brain regions at various periods (Additional file 1: Figure S4). Neither the genes involved in pressure (H2AFX, CDH2, KIF5C, PSMES, and PTPRM, Additional file 1: Figure S5), nor those involved in amino acid metabolism (PTPRM, Additional file 1: Figure S6), or development (YWHAQ, CDH2, and KIF1A/KIF5C, Additional file 1: Figure S7). Totally, the highly expressing genes in brain were constantly expressed across different brain regions during various development periods (YWHAQ, CDH2, and KIF1A/KIF5C, Additional file 1: Figure S8). It implied that many periods during brain development are pivotal for the etiology for ASD.
In this study, we explored the genotype–phenotype relationships in ASD, to facilitate ongoing efforts to explain the molecular mechanisms of their endo-phenotypes. We found that pathways related to protein synthesis, energy metabolism, and amino acid metabolism were significantly associated with DQ/IQ levels in ASD. Those that carried the mutations in their connection node (CACNA1A, ALG9, PALM2, MGAT4A, PCK2, PLEKHA1, PSME3, ADI1, and TLE3) obviously exhibited low DQ/IQ and language impairment.

In this study, we found that de novo mutations in probands occurred in 86 genes, including 22 related to ASD, and 26 associated with mental/developmental diseases. Because genes related to mental and developmental diseases are also potentially associated with ASD [68, 69], the 56% de novo altering genes (48/86) in this study are likely biologically related to

### Table 2 Association of mutations in selective pathways with clinical phenotypes

| Phenotypes | Protein synthesis | Pressure | Energy metabolism | Development | AA metabolism |
|------------|-------------------|---------|-------------------|------------|---------------|
|            | Related | Unrelated | Related | Unrelated | Related | Unrelated | Related | Unrelated | Related | Unrelated |
| Total genes | 47      | 24       | 23     | 48       | 15     | 56       | 37     | 34       | 12     | 59       |
| IQ/DQ < 60 | 16      | 17       | 7      | 26       | 2      | 31       | 18     | 15       | 2      | 31       |
| ≥ 60       | 22      | 6        | 11     | 17       | 10     | 18       | 15     | 13       | 8      | 20       |
| *P*        | 0.019   | 0.162    | 0.008  | 1.00     | 0.034  | 0.034    | 1.04   | 0.17     |        |          |

\*IQ: intelligence quotient. DQ: developmental quotient.

![Fig. 2 Protein–protein interaction for all de novo altering genes](image-url)
Table 3  Clinical phenotypes in carriers with the mutations in genes involving the three important pathways

| Case | Gene    | Sex | Diagnosed age | Father age (y)* | Mother age (y)* | DQ/IQ | Language | Walking age (m) | Hydroxyproline | Thyroid function | C13-C18 | C0-C6          |
|------|---------|-----|---------------|----------------|----------------|-------|----------|-----------------|----------------|-----------------|----------|----------------|
| K2   | ALG9 PALM2 | M   | 2.3           | 33             | 31             | 68    | NV       | 13              | Normal         | Normal          | Normal   | C2/C5 increased |
| AL4  | MGAT4A  | M   | 3             | 33             | 34             | 55    | NV       | 13              | NA             | Normal          | Normal   | C2 increased   |
| D3   | PK22 CAONA1A | M   | 2.8           | –              | –              | NA    | NV       | 15              | Decreased      | Normal          | Normal   | Normal         |
| AMS  | PLEXHA1 | M   | 3.2           | 28             | 26             | 61    | NV       | 11              | Normal         | Normal          | Normal   | C3 increased   |
| AG7  | PSME3   | M   | 3.4           | 34             | 33             | 60    | V        | 16              | NA             | FT3 increased | Normal   | C6 decreased   |
| V3A  | ADI1    | M   | 1.9           | 25             | 23             | 68    | NV       | 15              | Normal         | Normal          | Normal   | Normal         |
| R10  | TLE3    | M   | 3.3           | 26             | 23             | 99    | V        | 15              | Decreased      | Normal          | Normal   | C3-5 increased |

* The age when proband at birth

NV non-verbal. NA non-analyzed. FT3 free triiodothyronine
the occurrence of ASD. Moreover, the average number and rate of de novo SNV/INDEL, and the ratio of non-synonymous to synonymous de novo SNVs (NS:S) was similar to previous ASD studies [9]. Additionally, the quality of whole-exome sequencing is high (Additional file 1: Figures S1 and S2). Thus, we believe that our findings regarding genetic associations in ASD and ID are creditable. To our knowledge, this is the first time that de novo mutations associated with amino acid/protein/energy metabolism have been found to play a pivotal role in the etiology of ID in ASD. In this study, the nine de novo altering genes (CACNA1A, ALG9, PALM2, MGAT4A, PCK2, PLEKHA1, PSME3, ADI1, and TLE3) were involved in all the above important pathways simultaneously. Interestingly, they are all reported related to brain development. Among of them, CACNA1A is involved in protein synthesis (GO:0043231 and GO:0043234), energy metabolism (GO:0044262), and amino acid metabolism (ko004010), and is reported to the occurrence of ASD [26, 27]. And PALM2, ALG9, and TLE3 also participate in the above pathways such as GO:0043231, GO:0006487, ko01100, and ko04010, and all of them are reported to be ASD-relative [38, 39, 46]. MGAT4A, a schizophrenia-relevant gene [56], is involved in the GO:0006487, GO:0043234, and ko01100 pathways. The ADI1 and PLEKHA1 are involved in amino acid and derivative metabolism (R-HSA-71291), synthesis of PIPs at the plasma membrane (R-HSA-1660499) and energy metabolism (R-HSA-1430728), and are related to neuro-metabolic disease (Leigh syndrome; OMIM256000) and neuron developmental disease (congenital hypomyelinating neuropathy; OMIM605253), respectively. And PCK2 is reported to be associated with the etiology of ID [64]. Meanwhile, their mutations are the cause of an inherited metabolic disease (PEPCK deficiency, mitochondrial, OMIM: 261650), and it is also related to GO:0043231, ko00010, ko00620, and ko00020 pathways. Another gene PSME3 (also named as PA28γ or REGγ) is not reported relative to ASD or mental diseases in human previously. However, it is an e-QTR loci for the expression on many ASD-relative tissues, such as hippocampus, frontal cortex, and cingulate cortex [56]. And Psme3 gene transfer improves motor coordination in mouse model of Huntington’s disease [70]. This gene is involved in the pathways of amino acid and derivative metabolism (R-HSA-71291), ABC-family proteins-mediated transport (R-HSA-382556), APC/C-mediated degradation of cell cycle proteins (R-HSA-174143), and is reported to regulate energy homeostasis [71]. Our data suggest that a novel type of targets involving nodes of the important pathways modulating protein synthesis, energy production, and neurotransmission (BCAAs) simultaneously, might better explain some severe problems in ASD, such as comorbidity with ID and language impairment. Brain dysfunctions related to IQ and language development in ASD disrupt the transducing experience-mediated neural activity into long-term modifications of synapses [72]. In many cases, the long-term synaptic modifications rely upon new protein synthesis, including the following process: protein synthesis activated by the stimuli of neuron receptors (NMDSA), then regulation of the synthesis of synaptic signaling molecules (CaMKIIα, ion channels (SK channel), translation factors (eIF4E), and glutamate receptor subunits (GluA1, GluA2) [73–75]. These mechanisms for synaptic modifications and plasticity link brain protein synthesis with ID and language learning in ASD [76]. Amino acids, especially branched chain amino acids (BCAAs) which comprise as much as 30% of proteins in the cell, are also related to long-term modifications of synapses. By studying the mutation of BCKDK (a metabolizing enzyme of BCAAs) [77, 78] and SLC7A5 (a neutral amino acid transporter) [79], people know that these amino acids are also used as neurotransmitters and as metabolic intermediates in the etiology of ASD, ID, and other mental diseases [80]. Moreover, oxygen consumption, a major index for energy metabolism in the brain, accounts for about one-fifth of the total consumption of the human body. It has been proven that glycolysis and β-oxidation of fatty acid are important mechanisms closely related to brain development dysfunction in ASD [4]. Therefore, it makes sense that energy metabolism-related pathways play a vital role in the etiology of ID and language impairment in ASD. Taken together, our findings on the genetic association between the networks of amino acid/protein/energy-metabolism and ID in autism are biological feasible. Gene panel sequencing is thought to be helpful for screening ID phenotype in ASD patients. For instance, Redin et al. [81] reached a 25% diagnostic yield of ID/ASD comorbidity in 106 selected patients without con genital malformations, fragile X syndrome, or detectable CNV mutations, using a panel with 99 X-linked and 118 autosomal genes. Grozeva et al. [82] reported an 11% diagnostic rate on unselected 986 ASD patients with moderate to severe ID, using a larger panel of 565 genes. Aspromonte et al. [83] designed a smaller panel including 74 genes related to both ID and ASD, and reached a 27% diagnostic rate (41/150) in a careful selected ASD population with ID, who were negative for CNV and deletions/imprinting defects. By reviewing some references, Chirurazzi et al. suggested a panel of 174 genes (64 X-linked and 110 autosomal) to screen ID/ASD patients [10]. In this study, we suggested a panel of 9 genes to identify ASD patients with ID and non-verbal language with a 10% diagnostic yield, and it reached a similar diagnostic
rate in early diagnostic ASD patients with ID. Our findings are helpful for future disease diagnosis.

Additionally, NOTCH1 was found to have mutated recurrently in this study (c.G2995A:p.V999M and c.C3080T:p.S1027L). Human NOTCH1 gene (Gene ID:4851) encodes a member of the NOTCH protein family (belonging to Type I transmembrane protein family), which shares a characteristic structure: multiple extracellular epidermal growth factor-like (EGF) repeats. As a receptor, extracellular EGF repeats of NOTCH1 are pivotal for binding to its ligands, such as JAG1/2 and DLL1~3 (Fig. 1A) [24, 25]. After activation of these ligands, NOTCH1 receptor is hydrolyzed by ADAM10 metalloprotease and γ-secretase complex, then releases an intracellular fragment to nuclear, and participates in transcriptional regulation of many developmental genes, thus playing important roles in neurogenesis, vascularization, inflammation, and other processes (Fig. 1B) [17, 18, 25]. In this study, both V999M and S1027L de novo mutations were located in the EGF repeats, influencing the binding of NOTCH1 receptor with its ligands, disconnecting the networks of neuron-neuron and/or neuron/stroma cell, and hindering brain development, thus leading to the occurrence of ASD. Therefore, we postulate that the recurrent mutations in EGF_CA domain of NOTCH1 are related to and may be a risk factor of ASD. We believe these findings would be valuable for future etiologial study.

This study have some limitations: Our results must be interpreted with caution given the small sample sizes of both studies and challenges inherent in combining datasets.

Conclusion

Our data suggest that the connection nodes of the pathways such as amino acid/protein/energy-metabolism should be a novel type of target for ASD, which may play a vital role in the etiology of ID in ASD. Our findings suggest a panel of 9 genes to screen ASD patients with ID and language delay in this study. Moreover, the recurrent mutations in EGF_CA domain (EGF repeats) of NOTCH1 are associated with ASD, which implies a new disease mechanism. However, studies with larger population in different ethnic groups and functional studies are warranted to validate our findings.

Methods

Study population

From Oct 2015 to Jan 2017, we collected 79 children with ASD from a National Women and Children's Medical Center for the south central region in China. All these 79 patients (77 trios and 2 quarters) (male/female = 72/7; 3.19±1.24 years) met the following inclusion criteria consisting of Diagnosis and statistical Manual of Mental Diseases version-5 (DSM-5), Autism Diagnostic Interview-Revised (ADI-R), and Autism Diagnostic Observation Schedule (ADOS), and those who were initially diagnosed at the age of fewer than two years old would be followed up to obtain the definitive diagnosis when whose age was at least two years old. All included subjects had an extensive clinical evaluations including relevant demographic data collection, neurological assessments, developmental quotient (DQ) assessment by Gesell Development Diagnosis Scale (GDDS)/ intelligence quotient (IQ) assessment by Chinese Wechsler Intelligence Scale for children- IV Version (CWISC-IV) or by Chinese Wechsler Young Children Scale of Intelligence-IV Version (CWWYCSI-IV), and the testing of plasma levels of amino acids, acylcarnitines (C0-C18) via HPLC-GC/MS as well as thyroid function. Metabolic disturbances in plasma hydroxyproline, acylcarnitines, and thyroid function were defined as theirs levels increased or decreased more than twofold as compared to the norm reference. The non-verbal autistic child was defined as a child with spontaneous functional words less than five clinically. The study was approved by the Clinical Research Ethics Committee of Guangzhou Women's and Children's Medical Center, and informed consent for participation was obtained from either of their parents/guardians. Blood samples of the probands, parents, and other available relatives including siblings were obtained from who gave informed consent.

Exome capture and sequencing

Genomic DNA of the studied families (proband, both parents, and other available siblings) was extracted from the peripheral blood using the QIAamp DNA Blood Mini kit (QIAGEN GmbH, Hilden, Germany). We quantified initial DNA using a Qubit High Sensitivity Assay and checked sample purity using the Nanodrop OD260/280 ratio. Purified DNA was fragmented into an average size of 250 bp and hybridized by the Agilent V5 sequence capture array to capture the exonic DNA. We performed whole-exome sequencing with 100 bp pair-end reads on Illumina HiSeq 4000 platform following Illumina’s recommended protocol. The raw image files were processed using the standard Illumina Pipeline (version 1.3.4) for base calling with the default parameters.

Alignment and variant calling

After removing reads caught adapter sequence and low-quality sequences (rate of base with quality<5), the sequencing quality of all processed FASTQ files was measured by Fastqc (version 0.11.4). Pruned reads in the FASTQ format were aligned to the human reference genome (hg 19 version) by BWA (version 0.5.9-r16), and...
the duplicated sequence generated in the processing of PCR was marked by Picard (http://broadinstitute.github.io/picard). We utilized the Genome Analysis Toolkit (GATK; version 3.5) to perform the local realignment and base quality recalibration in the sequencing target region and its extension (500 bp) region and thereby obtained an ‘Analysis-Ready’ BAM file for each individual. The single nucleotide variants (SNV) and insertions and deletions (INDELS) were jointly called by HaplotypeCaller in GATK for every three or four members per family, and FamSeq was used to adjust variants based on family information. We further removed the mutations with a Variant Quality Score (VQSLOD) with a tranche sensitivity of less than 99.9% to alleviate other confounders’ effects. All output files, which generated in the universal variant call format (VCF), were annotated by ANNOVAR with various databases.

**Sample quality control**

Two methods were adopted for quality control checks in all samples: (1) Genotypes of 24 common mutations (frequency > 0.4 in Eastern Asian of 1000 Genome Project) were tested by Mass Spectrum, and the concordance of initial DNA’s genotype and sequencing data should be no less than 0.95; (2) Mendelian rate of each family should be no larger than 0.5%.

**Splicing site prediction**

We used three tools (including NetGene2, SplicePort, and Human Splicing Finder) to predict whether a silent or missense de novo mutation can lead to candidate transcript splicing. Mutations judged as candidate splicing sites by at least two of above-mentioned programs would be marked as silent-splicing or missense-splicing and would be regarded as splicing mutation in this study.

**Inherited mutations**

In addition to de novo mutations, three types of inherited mutations that may lead to ASD were also extracted: (1) rare (minor allele frequency < 1% in East Asian of 1000 Genome Project and ExAC) homozygous coding mutations that transmitted from heterozygous parents; (2) rare compound heterozygous coding mutations that transmitted from heterozygous parents; (3) rare heterozygous coding mutations of male proband, which transmitted from maternal X chromosome. We also picked up the private inherited mutations (rare heterozygous mutations that inherited from father or mother, and only observed in single family) to compare with the de novo mutations. All above-inherited SNVs and INDELS have a good genotype quality (phred values greater than 20, sequencing depth larger than 10×).

**Pathways, protein–protein interaction, and co-expression networks**

All de novo altering genes were annotated by GO (http://www.geneontology.org) and KEGG pathway database (http://www.genome.jp/kegg/pathway.html). The protein–protein interaction networks of these altering genes were constructed for all potential harmful genes based on DAPPLE (Disease Association Protein–Protein Link Evaluator) and STRING (http://string-db.org), and the co-expression network was built with the Brain-Span Atlas resource. Expression data of samples before early childhood (age < 6 years) in multiple brain regions (including CBC, CB, HIP, AMY, and STR) were used. We used person test to estimate the co-expression based on periods and brain regions, respectively.

**Statistical analysis**

Chi-square test and logistic analysis were used to analyze the data in standard R packages. A two-sided \( P \) value of < 0.05 defined statistical significance.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s40246-022-00427-7.

**Acknowledgements**

Not applicable.

**Author contributions**

YPT, WXC, and BL helped in concept and design, WXC, BL, MT, XX, JF, ZFH, TT, YPT contributed to acquisition, analysis, or interpretation of data; WXC and BL drafted the manuscript; YPT critically revised the manuscript. All authors read and approved the final manuscript.

**Funding**

The project was partially supported by the major Scientific and Technological Projects of Brain Science and Brain-like Research of Guangzhou (202007030002) and the Research and Development Plan Projects in the key areas of Guangdong Province of China (2018B030335001) to YPT and by the grants of Science and Technology Department of Guangdong Province of
References:

1. Taylor JL, Henninger NA, Mallick MR. Longitudinal patterns of employment and postsecondary education for adults with autism and average range IQ. Autism: Int J Res Pract. 2015;19(7):785–93.

2. Bal VH, Fok M, Lord C, Smith IH, Mirenda P, Szatmari P, et al. Predictors of longer-term development of expressive language in two independent longitudinal cohorts of language-delayed preschoolers with autism spectrum disorder. J Child Psychol Psychiatry. 2020;61(7):826–35.

3. Bugajska J, Ochocińska A, Chojnowska S, Borzym-Kluczyk M, Skorupa E, et al. Inherited and de novo genetic risk for autism impacts shared patterns of gene regulation and neurological disease heritability. Nat Neurosci. 2021;24(3):437–48.

4. Kępka A, Ochocińska A, Chojnowska S, Borzym-Kluczyk M, Skorupa E, Knat M, et al. Potential role of L-carnitine in autism spectrum disorder. J Clin Med. 2021;10(6):1202.

5. Liu X, Sun X, Sun C, Zou M, Chen Y, Huang J, et al. Prevalence of epilepsy in autism spectrum disorders: a systematic review and meta-analysis. Autism: Int J Res Pract. 2020;26(37):4789–95.

6. Vissers L, van Nimwegen KJM, Schieving JH, Kamsteeg EJ, Kleefstra T, et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell. 2020;180(3):568–64.e23.

7. Chiurazzi P, Kiani AK, Mierutus J, Paolacci S, Barati S, Manara E, et al. Genetic analysis of intellectual disability and autism. Acta Bio-Med. Atenei Parm. 2020;91(13-s):e2020003.

8. Chen P, Li Z, Li Y, Ahmad SS, Kamal MA, Hoo X. The language development via FOXP2 in autism spectrum disorder: a review. Curr Pharm Des. 2020;26(37):4789–95.

9. Kato H, Kushima I, Mori D, Yoshimi A, Aliksi B, Nava Y, et al. Rare genetic variants in the gene encoding histone lysine demethylase 4C (KDM4C) and their contributions to susceptibility to schizophrenia and autism spectrum disorder. Transl Psychiatry. 2020;10(1):421.

10. DiCarlo GE, Aguilar JL, Narr KE, Casillas D, Siegel SW, et al. Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine-dependent behaviors. J Clin Invest. 2019;129(8):3407–19.

11. Gill PS, Clothier JL, Veerapandian D, Awee H, Porter-Gill PA, Schaefer GB. Molecular dysregulation in autism spectrum disorder. J Pers Med. 2021;11(9):848.

12. Kim N, Kim KH, Lim WJ, Kim J, Kim SA, Yoo HJ. Whole exome sequencing identifies novel de novo variants interacting with six gene networks in autism spectrum disorder. Genes. 2020;12(11):1.

13. Iossifov I, O’Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515(7526):216–21.

14. Kim N, Kim KH, Lim WJ, Kim J, Kim SA, Yoo HJ. Whole exome sequencing identifies novel de novo variants interacting with six gene networks in autism spectrum disorder. Genes. 2020;12(11):1.

15. Kato H, Kushima I, Mori D, Yoshimi A, Aliksi B, Nava Y, et al. Rare genetic variants in the gene encoding histone lysine demethylase 4C (KDM4C) and their contributions to susceptibility to schizophrenia and autism spectrum disorder. Transl Psychiatry. 2020;10(1):421.
30. Yuen RKC, Merico D, Bookman M, Howe JL, Thiruvahindrapuram B, Patel RV, Whitney J, et al. Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder. Nat Neurosci. 2017;20(4):602–11.

31. Lin VC, Frei JA, Kilander MB, Shen W, Blatt GJ. A subset of autism-associated genes regulate the structural stability of neurons. Front Cell Neurosci. 2016;10:263.

32. de Ligt J, Willemsen MH, van Bon BW, Kleefstra T, Yntema HG, Kroeis T, et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med. 2012;367(20):1921–9.

33. Tomasselli PJ, Rosser AM, Horga A, Laura M, Blake JC, Houlden H, et al. A de novo dominant mutation in KIF1A associated with axonal neuropathy, spasticity and autism spectrum disorder. J Peripher Nerv Syst. 2017;22(4):460–3.

34. Martin J, Cooper M, Hamshere ML, Pocklington A, Scherer SW, Kent L, Tomaselli PJ, Rossor AM, Horga A, Laura M, Blake JC, Houlden H, et al. A parallel profiling of DNA methylation and hydroxymethylation highlights the ERMN gene in autism spectrum disorders. Transl Psychiatry. 2016;6(7):e855.

35. Smith AR, Smith RG, Pishva E, Hannon E, Roubroeks JAY, Burrage J, et al. MARK2-dependent phosphorylation of Tau in Alzheimer's disease. J Alzheimer's Dis: JAD. 2013;33(3):699–713.

36. Guan J, Yang E, Yang J, Zeng Y, Ji G, Cai JJ. Exploiting aberrant mRNA expression in autism for gene discovery and diagnosis. Hum Genet. 2016;135(7):797–811.

37. Pathak MM, Nourse JL, Tran T, Hwe J, Arulmoli J, Wilson GR, et al. De novo and rare inherited copy-number variations in the hemiplegic form of cerebral palsy. Genet Med. 2018;20(2):172–80.

38. Halperin D, Kadir R, Perez Y, Drabkin M, Yoge Y, Wormser O, et al. SEC31A mutation affects ER homeostasis, causing a neurological syndrome. J Med Genet. 2019;56(3):139–48.

39. Gereklis A, Sarip T, Haffner-Krausz R, Olender T, Woodruff TM, Reiner O. Developmental activities of the complement pathway in migrating neurons. Nat Commun. 2017;8:15096.

40. Kuwano Y, Kamio Y, Kawai T, Katsuura S, Inada N, Takaki A, et al. Autism spectrum disorder: evidence from copy number variants. J Am Acad Child Adolesc Psychiatry. 2014;53(7):761–70.e26.

41. Lin Y, Afshar S, Rajadhyaksha AM, Potash JB, Han S. A machine learning approach to predicting autism risk genes: validation of known genes and discovery of new candidates. Front Genet. 2020;11:50064.

42. Conroy J, McGettigan P, Murphy R, Webb D, Murphy SM, McCoy B, et al. A novel focus for episodic ataxia: UBAP1 the likely candidate. Eur J Hum Genet. EJHG. 2014;22(4):505–10.

43. Haenig C, Atias N, Taylor AK, Mazza A, Schaefer MH, Russ J, et al. Interactome mapping provides a network of neurodevelopmental disease proteins and uncovers widespread protein aggregation in affected brains. Cell Rep. 2020;32(7):108050.

44. Gross CJ, Bassel-Goodrich JN. Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders. Front Mol Neurosci. 2014;7:12.

45. Pathak MM, Nourse JL, Tran T, Hwe J, Arulmoli J, Le DT, et al. Stretch-activated ion channel Piezo1 directs lineage choice in human neural stem cells. Proc Natl Acad Sci USA. 2014;111(45):16148–53.

46. Lei Y, Zhu H, Yang W, Ross ME, Shaw GM, Finnell RH. Identification of novel CELSR1 mutations in spina bifida. PLoS ONE. 2014;9(3):e92207.

47. Smith AR, Smith RG, Pishva E, Hannon E, Roubroeks JAY, Burrage J, et al. Protein network analysis reveals selectively vulnerable regions and biological processes in FTD. Neurogenet. 2018;8(5):e266.

48. Meda SA, Ruaño G, Windemuth A, O’Neil K, Berwise C, Dunn SM, et al. Parallel profiling of DNA methylation and hydroxymethylation highlights neurodevelopmental defects and implication of the ERMN gene in autism spectrum disorders. Transl Psychiatry. 2016;6(7):e855.

49. Smith AR, Smith RG, Pishva E, Hannon E, Roubroeks JAY, Burrage J, et al. Parallel profiling of DNA methylation and hydroxymethylation highlights neurodevelopmental defects and implication of the ERMN gene in autism spectrum disorders. Transl Psychiatry. 2016;6(7):e855.

50. Zareei M, Fehlings DL, Mawjee K, Switzer L, Thiruvahindrapuram B, Walker S, et al. De novo and rare inherited copy-number variations in the hemiplegic form of cerebral palsy. Genet Med. 2018;20(2):172–80.

51. Lachman HM. Copy variations in schizophrenia and bipolar disorder. CytoGenet Genome Res. 2008;123(1–4):3–27.

52. Gorodkin A, Sarip T, Haffner-Krausz R, Olender T, Woodruff TM, Reiner O. Developmental activities of the complement pathway in migrating neurons. Nat Commun. 2017;8:15096.
73. Shrestha A, Sultana R, Lee CC, Ogundele OM. SK channel modulates synaptic plasticity by tuning CaMKIIα/β dynamics. Front Synaptic Neurosci. 2019;11:18.
74. Xu ZX, Kim GH, Tan JW, Riso AE, Sun Y, Xu EY, et al. Elevated protein synthesis in microglia causes autism-like synaptic and behavioral aberrations. Nat Commun. 2020;11(1):1797.
75. Ye J, Yin Y, Liu H, Fang L, Tao X, Wei L, et al. Tau inhibits PKA by nuclear proteasome-dependent PKAR2α elevation with suppressed CREB/GluA1 phosphorylation. Aging Cell. 2020;19(1):e13055.
76. Aincy M, Meziane H, Heraud T, Humeau Y. Synaptic dysfunction in amygdala in intellectual disorder models. Prog Neuropsychopharmacol Biol Psychiatry. 2018;84(Pt B):392–7.
77. Oyarzabal A, Bravo-Alonso I, Sánchez-Aragó M, Rejas MT, Merinero B, García-Cazorla A, et al. Mitochondrial response to the BCKDK-deficiency: some clues to understand the positive dietary response in this form of autism. Biochem Biophys Acta. 2016;1862(4):592–600.
78. Cheon S, Kaur K, Nijem N, Tuncay IO, Kumar P, Dean M, et al. The ubiquitin ligase UBE3B, disrupted in intellectual disability and absent speech, regulates metabolic pathways by targeting BCKDK. Proc Natl Acad Sci USA. 2019;116(9):3662–7.
79. Colón-Rodríguez A, Uribe-Salazar JM, Weyenberg KB, Sriram A, Quezada A, Kaya G, et al. Assessment of autism zebrafish mutant models using a high-throughput larval phenotyping platform. Front Cell Dev Biol. 2020;8:586296.
80. Cascio L, Chen CF, Pauly R, Srikanth S, Jones K, Skinner CD, et al. Abnormalities in the genes that encode large amino acid transporters increase the risk of Autism spectrum disorder. Mol Genet Genomic Med. 2020;8(1):e1036.
81. Redin C, Gerard B, Lauer J, Herenger Y, Muller J, Quartier A, et al. Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing. J Med Genet. 2014;51(11):724–36.
82. Grozeva D, Carss K, Spasic-Boskovic O, Tejada MI, Gecz J, Shaw M, et al. Targeted next-generation sequencing analysis of 1000 individuals with intellectual disability. Hum Mutat. 2015;36(12):1197–204.
83. Aspromonte MC, Bellini M, Gasparini A, Cerraro M, Bettella E, Polli R, et al. Characterization of intellectual disability and autism comorbidity through gene panel sequencing. Hum Mutat. 2019;40(9):1346–63.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.